US FDA to review license extension for atezolizumab in combination with bevacizumab for unresectable hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy

This application is based on the results of the phase III IMbrave150 study, which demonstrated that atezolizumab with bevacizumab reduced the risk of death (overall survival) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42-0.79; p=0.0006) compared with sorafenib.


Biospace Inc.